Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 7

1.

Evaluating New Compounds to Treat Burkholderia pseudomallei Infections.

Ross BN, Myers JN, Muruato LA, Tapia D, Torres AG.

Front Cell Infect Microbiol. 2018 Jun 25;8:210. doi: 10.3389/fcimb.2018.00210. eCollection 2018.

2.

Development of Subunit Vaccines That Provide High-Level Protection and Sterilizing Immunity against Acute Inhalational Melioidosis.

Burtnick MN, Shaffer TL, Ross BN, Muruato LA, Sbrana E, DeShazer D, Torres AG, Brett PJ.

Infect Immun. 2017 Dec 19;86(1). pii: e00724-17. doi: 10.1128/IAI.00724-17. Print 2018 Jan.

3.

Use of Reverse Vaccinology in the Design and Construction of Nanoglycoconjugate Vaccines against Burkholderia pseudomallei.

Muruato LA, Tapia D, Hatcher CL, Kalita M, Brett PJ, Gregory AE, Samuel JE, Titball RW, Torres AG.

Clin Vaccine Immunol. 2017 Nov 6;24(11). pii: e00206-17. doi: 10.1128/CVI.00206-17. Print 2017 Nov.

4.

From In silico Protein Epitope Density Prediction to Testing Escherichia coli O157:H7 Vaccine Candidates in a Murine Model of Colonization.

Tapia D, Ross BN, Kalita A, Kalita M, Hatcher CL, Muruato LA, Torres AG.

Front Cell Infect Microbiol. 2016 Aug 30;6:94. doi: 10.3389/fcimb.2016.00094. eCollection 2016.

5.

Burkholderia mallei CLH001 Attenuated Vaccine Strain Is Immunogenic and Protects against Acute Respiratory Glanders.

Hatcher CL, Mott TM, Muruato LA, Sbrana E, Torres AG.

Infect Immun. 2016 Jul 21;84(8):2345-54. doi: 10.1128/IAI.00328-16. Print 2016 Aug.

6.

Melioidosis: where do we stand in the development of an effective vaccine?

Muruato LA, Torres AG.

Future Microbiol. 2016;11(4):477-80. doi: 10.2217/fmb-2015-0018. Epub 2016 Apr 15. No abstract available.

7.

Recent Advances in Burkholderia mallei and B. pseudomallei Research.

Hatcher CL, Muruato LA, Torres AG.

Curr Trop Med Rep. 2015 Jun;2(2):62-69.

Supplemental Content

Loading ...
Support Center